Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | ALPL | P05186 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243946 | 0.90 | KMT2A (0.67) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL23847019 | 0.86 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL23846503 | 0.85 | SMN1; SMN2 (0.71) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL23846535 | 0.85 | ALPL (0.59) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL23846666 | 0.82 | KMT2A (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL25754681 | 0.80 | MEN1 (0.73) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL28504349 | 0.80 | HTR6 (0.57) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL23846529 | 0.79 | ALPL (0.60) | MEN1KMT2ASMN1; SMN2ALPLGAA | |
| SCHEMBL23833758 | 0.78 | RECQL (0.73) | SMN1; SMN2ALDH1A1ALPLGAALMNA | |
| SCHEMBL17980891 | 0.78 | MAPT (0.60) | MEN1KMT2ASMN1; SMN2ALDH1A1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | MEN1 3902/4885KMT2A 4864/4885SMN1; SMN2 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.